COVID-19 vaccine booster strategy: striving for best practice.
作者信息
Tanriover Mine Durusu, Akova Murat
机构信息
Department of Internal Medicine, Vaccine Institute, Hacettepe University School of Medicine, Ankara, Turkey.
Department of Infectious Diseases, Vaccine Institute, Hacettepe University School of Medicine, Ankara, Turkey.
出版信息
Lancet Glob Health. 2022 Jun;10(6):e774-e775. doi: 10.1016/S2214-109X(22)00204-2. Epub 2022 Apr 23.
Abstract
摘要
相似文献
1
COVID-19 vaccine booster strategy: striving for best practice.2019冠状病毒病疫苗加强免疫策略：追求最佳实践
Lancet Glob Health. 2022 Jun;10(6):e774-e775. doi: 10.1016/S2214-109X(22)00204-2. Epub 2022 Apr 23.
2
Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign.主要 COVID-19 疫苗接种周期和加强剂量的效果：意大利全国疫苗接种运动分析。
Eur J Public Health. 2022 Apr 1;32(2):328-330. doi: 10.1093/eurpub/ckab220.
3
SARS-CoV-2 Booster Vaccine Response among Patients Receiving Dialysis.接受透析患者的新型冠状病毒2型加强疫苗反应
Clin J Am Soc Nephrol. 2022 Jul;17(7):1036-1038. doi: 10.2215/CJN.00890122. Epub 2022 Apr 5.
4
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.新型冠状病毒肺炎疫苗接种计划启动后，免疫缺陷病（IEI）患者接种新型冠状病毒肺炎加强针的免疫原性及其一年临床随访
Front Immunol. 2024 Apr 18;15:1390022. doi: 10.3389/fimmu.2024.1390022. eCollection 2024.
5
Strategies and safety considerations of booster vaccination in COVID-19.COVID-19 加强针接种的策略和安全性考虑。
Bosn J Basic Med Sci. 2022 Jun 1;22(3):366-373. doi: 10.17305/bjbms.2021.7082.
6
Adjudicating the logistics of COVID-19 vaccine boosters from a global perspective.从全球视角裁定 COVID-19 疫苗加强针的物流问题。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2020572. doi: 10.1080/21645515.2021.2020572. Epub 2022 Jan 13.
7
Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety.加强针接种策略：必要性、免疫目标、免疫策略和安全性。
J Med Virol. 2022 Jun;94(6):2369-2375. doi: 10.1002/jmv.27590. Epub 2022 Jan 19.
8
9
Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.不同 COVID-19 疫苗平台作为加强针的可互换性：一项模拟真实世界实践的 3 期研究。
Vaccine. 2024 Jul 25;42(19):3989-3998. doi: 10.1016/j.vaccine.2024.05.009. Epub 2024 May 17.
10
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.科里纳平（COReNAPCIN）作为一种 SARS-CoV-2 mRNA 疫苗，在健康伊朗成年人中作为第四种异源加强针的安全性和免疫原性：一项双盲、随机、安慰剂对照、为期 6 个月随访的 1 期临床试验。
Int Immunopharmacol. 2024 Jun 15;134:112192. doi: 10.1016/j.intimp.2024.112192. Epub 2024 May 17.
引用本文的文献
1
Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape.COVID-19 疫苗领域新兴的异源 mRNA 增强策略。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2153532. doi: 10.1080/21645515.2022.2153532. Epub 2023 Jan 11.
2
Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine.三种剂量 BNT162b2 mRNA SARS-CoV-2 疫苗的先天免疫应答。
Front Immunol. 2022 Aug 22;13:947320. doi: 10.3389/fimmu.2022.947320. eCollection 2022.
3
Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries.抗新冠病毒疫苗加强针：OECD 和欧盟国家实施政策概述。
Int J Environ Res Public Health. 2022 Jun 13;19(12):7233. doi: 10.3390/ijerph19127233.
本文引用的文献
1
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.BNT162b2 和科兴疫苗一剂、两剂和三剂对香港 COVID-19 的疫苗有效性：基于人群的观察性研究。
Lancet Infect Dis. 2022 Oct;22(10):1435-1443. doi: 10.1016/S1473-3099(22)00345-0. Epub 2022 Jul 15.
2
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.同源和异源加强针对于灭活 SARS-CoV-2 疫苗的有效性：一项大规模前瞻性队列研究。
Lancet Glob Health. 2022 Jun;10(6):e798-e806. doi: 10.1016/S2214-109X(22)00112-7. Epub 2022 Apr 23.
3
Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old.55岁以上人群对灭活冠状病毒疫苗的T细胞和抗体反应降低。
Front Immunol. 2022 Mar 1;13:812126. doi: 10.3389/fimmu.2022.812126. eCollection 2022.
4
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases.同源灭活 SARS-CoV-2 疫苗第三剂接种后在大量自身免疫性风湿病患者中免疫原性增加。
Ann Rheum Dis. 2022 Jul;81(7):1036-1043. doi: 10.1136/annrheumdis-2021-222096. Epub 2022 Mar 11.
5
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎（B.1.1.529）变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
6
Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.BNT162b2与新冠疫苗科兴平台联合使用针对奥密克戎变种的抗体反应
Vaccines (Basel). 2022 Jan 21;10(2):160. doi: 10.3390/vaccines10020160.
7
Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.第二剂 COVID-19 疫苗接种后 9 个月内的感染、住院和死亡风险：瑞典的一项回顾性、全人群队列研究。
Lancet. 2022 Feb 26;399(10327):814-823. doi: 10.1016/S0140-6736(22)00089-7. Epub 2022 Feb 4.
8
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.科兴新冠疫苗加强免疫的免疫原性和安全性，以及两剂接种程序的免疫持久性：两项单中心、双盲、随机、安慰剂对照的 2 期临床试验的中期结果。
Lancet Infect Dis. 2022 Apr;22(4):483-495. doi: 10.1016/S1473-3099(21)00681-2. Epub 2021 Dec 8.
Zotero 插件